首页>
外国专利>
METHOD FOR THE EARLY DETECTION OF ACUTE KIDNEY INJURY IN CRITICAL PATIENTS, USING FIBROBLAST GROWTH FACTOR 23, KLOTHO AND ERYTHROPOIETIN AS BIOMARKERS
METHOD FOR THE EARLY DETECTION OF ACUTE KIDNEY INJURY IN CRITICAL PATIENTS, USING FIBROBLAST GROWTH FACTOR 23, KLOTHO AND ERYTHROPOIETIN AS BIOMARKERS
The invention relates to an ex vivo method for the early detection of acute kidney injury in critical patients, comprising the use of measurements of fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO) as biomarkers, where such measurements are obtained from a venous blood sample or urine, and allow the following factors to be calculated: 1 = ([FGF23]p x [EPO]p); 2 = ([FGF23]p / [Klotho]p); 3 = ([EPO]p) / [Klotho]p); 4 = (([FGF23]p x [EPO]p) / [Klotho]p); where [X]p is the measurement of the plasma level of X and X is selected from fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO). If the value of the indicator 1, 2, 3, 4 or two or more thereof, is higher than, or equal to, a cut-off point (10 U) which allows identification of patients with and without AKL with a high level of sensitivity/specificity, then a high probability of presence/development of AKI is confirmed, and measures can be taken for patients with AKI. If the indicator value 1, 2, 3, 4 or two or more thereof is lower than the previously mentioned cut-off point, then the probability of presence/development of AKI is low and standard treatment can be carried out, that is, with use of endovenous solutions, prevention of the use of nephrotoxins, use of renal replacement therapy in severe AKI, inter alia.
展开▼
机译：本发明涉及用于在危重患者中早期检测急性肾损伤的离体方法，其包括使用成纤维细胞生长因子23（FGF23），klotho（KL）和促红细胞生成素（EPO）的测量作为生物标记，其中这种测量是从静脉血样或尿液中获取，并允许计算以下因素：1 =（[FGF23] px [EPO] p）; 2 =（[FGF23] p / [Klotho] p）; 3 =（[EPO] p）/ [Klotho] p）; 4 =（（[[FGF23] p x [EPO] p）/ [Klotho] p）;其中[X] p是X血浆水平的测量值，X选自成纤维细胞生长因子23（FGF23），klotho（KL）和促红细胞生成素（EPO）。如果指标1、2、3、4或其中两个或更多个的值大于或等于一个临界点（10 U），则该临界点可识别高水平和低水平的AKL患者敏感性/特异性，则证实存在/发展为AKI的可能性很高，可以对AKI患者采取措施。如果指标值1、2、3、4或两个或更多个值低于前面提到的临界点，则AKI出现/发展的可能性很低，可以进行标准治疗，即使用静脉内溶液，预防使用肾毒素，在严重的AKI中使用肾脏替代疗法等。
展开▼
